How Dry Am I? A Case-Based Guide to Treating Retinal Vascular Diseases

How Dry Am I? A Case-Based Guide to Treating Retinal Vascular Diseases is organized by Paradigm Medical Communications, LLC.

Release Date: April 10, 2024
Expiration Date: April 10, 2025

Description:
Anatomic outcomes are a critical measure of both disease activity and treatment success in neovascular retinal diseases. Attaining “retinal dryness” treating with anti-vascular endothelial growth factor (VEGF) therapy can be elusive and/or burdensome for a significant number of patients. Dual inhibition of angiopoietin 2 (Ang-2) and VEGF has demonstrated efficacy providing similar visual outcomes but enhanced reduction of retinal fluid for patients with neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO) with greater durability compared with anti-VEGF monotherapy. Whiteboard animations highlight the rationale and anatomic benefits of Ang-2 inhibition to illustrate the clinical application of dual Ang-2/VEGF inhibition in the case series of patients with nAMD, DME, and RVO with persistent fluid. Each case study will answer the questions, “How dry am I?” and, importantly, “How dry can I get?” and “With how many injections?”

Learning Objectives:
Upon completion of this activity, participants should be able to:

• Describe the significance of macular leakage in neovascular retinal diseases
• Identify key anatomic data from trials comparing dual inhibition regimens with anti-VEGF alone in nAMD and DME 
• Formulate treatment plans for patients with nAMD and DME that demonstrate appropriate use of anatomic outcomes in decision-making, including agent selection and dosing intervals